Research programme: melanocortin-4 receptor agonists - Rhythm Pharmaceuticals

Drug Profile

Research programme: melanocortin-4 receptor agonists - Rhythm Pharmaceuticals

Alternative Names: BIM 22103

Latest Information Update: 19 Jun 2012

Price : $50

At a glance

  • Originator Ipsen
  • Developer Ipsen; Rhythm
  • Class Peptides
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 19 Jun 2012 Development is ongoing in USA
  • 19 Jun 2012 No development reported - Preclinical for Obesity in France (unspecified route)
  • 12 Mar 2010 Ipsen grants Rhythm Pharmaceuticals an exclusive worldwide licence for research, development and commercialisation of its melanocortin agonists
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top